BioWorld

Sep. 22, 2006

Merck KGaA Buying Serono, Giving CHF16.6B Valuation

Merck KGaA agreed to acquire a controlling stake in Serono SA by purchasing the Bertarelli family's shares in the company, which represent 64.5 percent of its equity and 75.5 percent of its voting rights. (BioWorld Today) Read More

Phase II Alzheimer's Results Boost Shares Of Medivation

Alzheimer's, Like Prion Disease, 'Seeded' By Misshapen Proteins

Alexion Seeks FDA Approval For Soliris In PNH Indication

Axcan Drops ITAX In Functional Dyspepsia After Phase III Failure

Biogen Joins With Alnylam On RNAi Therapies For PML

Clinic Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 12, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...